Inhibikase Therapeutics (NYSE:IKT) is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule kinase inhibitors for the treatment of neurological disorders. The company’s proprietary platform targets pathways implicated in Parkinson’s disease, Gaucher disease and other neurodegenerative conditions by modulating enzymes such as c-Abl and glucocerebrosidase. Its lead investigational candidate, IkT-148009, is a next-generation c-Abl inhibitor designed to cross the blood-brain barrier and has advanced into mid-stage clinical trials for slowing disease progression in Parkinson’s and related synucleinopathies. In addition, Inhibikase is progressing IkT-001 for the treatment of neuronopathic Gaucher disease and exploring new indications for its kinase inhibitor portfolio.
Founded in 2016 and originally headquartered in Cambridge, United Kingdom, Inhibikase has established research operations in both the U.K. and the United States, with its corporate office in Massachusetts. The company has assembled a network of strategic collaborations with leading academic centers and contract research organizations across North America and Europe to support its preclinical research and clinical trial programs. By leveraging its kinase inhibitor engine, Inhibikase aims to address significant unmet needs in neurodegeneration and rare genetic diseases that lack effective disease-modifying therapies.
Inhibikase’s leadership team brings together seasoned drug development veterans and biotech entrepreneurs with deep expertise in neurology and rare diseases. Chief Executive Officer Scott Mackintosh, Ph.D., has over two decades of experience guiding clinical-stage programs in neuroscience, while Chief Medical Officer Brian Sedo, M.D., has led multiple neurology trials in Parkinson’s disease. The board of directors and scientific advisory board include industry experts in medicinal chemistry, translational medicine and regulatory affairs, positioning the company to navigate complex development pathways and engage with global health authorities.
With a commitment to advancing novel therapies for patients living with devastating neurological conditions, Inhibikase is executing a multi-pronged clinical development plan. The company is actively recruiting participants for its Parkinson’s disease studies and is in ongoing dialogue with patient advocacy groups to ensure trials address patient needs. As Inhibikase progresses its pipeline, it remains focused on building a sustainable framework for innovation, strategic partnerships and future growth in the global neurology market.
